Please login to the form below

Not currently logged in
Email:
Password:

elosulfase alfa

This page shows the latest elosulfase alfa news and features for those working in and with pharma, biotech and healthcare.

BioMarin's real world data sways NICE on orphan drug Vimizim

BioMarin's real world data sways NICE on orphan drug Vimizim

NICE has issued final draft guidance recommending BioMarin Pharma's Vimizim (elosulfase alfa) for the treatment of the rare genetic disorder Morquio A syndrome. ... disease, and that health and quality of life improved significantly in some patients

Latest news

More from news
Approximately 2 fully matching, plus 2 partially matching documents found.

Latest Intelligence

  • Deal Watch October 2015 Deal Watch October 2015

    Sales of the product will fit well into BioMarin's commercial infrastructure for its enzyme replacement therapies Naglazyme (galsulfase), for the treatment of Mucopolysaccharidosis VI, and Vimizim (elosulfase alfa) for Morquio

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Synergy Vision

Synergy Vision believe in delivering medical communications that make a difference to healthcare professionals and patients. Our synergy of pharma...

Latest intelligence

The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...
Unique forum will unite NHS and industry to drive innovation
HSJ Life Sciences Forum will explore key NHS challenges and debate future of medicines, by Sarah Eglington, Client Services Director at Wilmington Healthcare...

Infographics